| Title |
Current and emerging pharmacological treatments for sarcoidosis: a review
|
|---|---|
| Published in |
Drug Design, Development and Therapy, April 2013
|
| DOI | 10.2147/dddt.s31064 |
| Pubmed ID | |
| Authors |
Scott H Beegle, Kerry Barba, Romel Gobunsuy, Marc A Judson |
| Abstract |
The treatment of sarcoidosis is not standardized. Because sarcoidosis may never cause significant symptoms or organ dysfunction, treatment is not mandatory. When treatment is indicated, oral corticosteroids are usually recommended because they are highly likely to be effective in a relative short period of time. However, because sarcoidosis is often a chronic condition, long-term treatment with corticosteroids may cause significant toxicity. Therefore, corticosteroid sparing agents are often indicated in patients requiring chronic therapy. This review outlines the indications for treatment, corticosteroid treatment, and corticosteroid sparing treatments for sarcoidosis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| South Africa | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Israel | 1 | 1% |
| Colombia | 1 | 1% |
| Australia | 1 | 1% |
| Unknown | 89 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 15 | 16% |
| Student > Bachelor | 13 | 14% |
| Student > Master | 12 | 13% |
| Researcher | 11 | 12% |
| Other | 10 | 11% |
| Other | 21 | 23% |
| Unknown | 11 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 58 | 62% |
| Agricultural and Biological Sciences | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Nursing and Health Professions | 3 | 3% |
| Other | 4 | 4% |
| Unknown | 15 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2015.
All research outputs
#7,959,659
of 25,371,288 outputs
Outputs from Drug Design, Development and Therapy
#543
of 2,268 outputs
Outputs of similar age
#65,507
of 212,987 outputs
Outputs of similar age from Drug Design, Development and Therapy
#9
of 20 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,987 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.